Cliff Asness's SPRY Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 25,877 shares of ARS Pharmaceuticals, Inc. (SPRY) worth $207,791, representing 0.00% of the portfolio. First purchased in 2022-Q1, this short-term holding has been held for 7 quarters.
Based on 13F filings, Cliff Asness has maintained this position in SPRY for several quarters, showing initial confidence in the investment. Largest addition occurred in Q1 2026, adding 25,877 shares. Largest reduction occurred in Q3 2022, reducing 19,845 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's ARS Pharmaceuticals (SPRY) Holding Value Over Time
Track share changes against reported price movement
Quarterly ARS Pharmaceuticals (SPRY) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +25,877 | New Buy | 25,877 | $8.03 |
| Q3 2025 | -16,132 | Sold Out | 0 | $0.00 |
| Q2 2025 | +5,016 | Add 45.12% | 16,132 | $17.45 |
| Q1 2025 | +11,116 | New Buy | 11,116 | $12.58 |
| Q3 2022 | -19,845 | Sold Out | 0 | $0.00 |
| Q2 2022 | +8,896 | Add 81.25% | 19,845 | $4.23 |
| Q1 2022 | +10,949 | New Buy | 10,949 | $3.47 |
Cliff Asness's ARS Pharmaceuticals Investment FAQs
Cliff Asness first purchased ARS Pharmaceuticals, Inc. (SPRY) in Q1 2022, acquiring 10,949 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held ARS Pharmaceuticals, Inc. (SPRY) for 7 quarters since Q1 2022.
Cliff Asness's largest addition to ARS Pharmaceuticals, Inc. (SPRY) was in Q1 2026, adding 25,877 shares worth $207,791.
According to the latest 13F filing for Q1 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 25,877 shares of ARS Pharmaceuticals, Inc. (SPRY), valued at approximately $207,791.
As of the Q1 2026 filing, ARS Pharmaceuticals, Inc. (SPRY) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in ARS Pharmaceuticals, Inc. (SPRY) was 25,877 shares, as reported at the end of Q1 2026.